●
Repeat investment signals continued conviction
in Biopeak’s approach to longevity and preventive care in India
●
Capital to expand multidisciplinary
specialist-led clinics, diagnostics, proprietary AI and research, including a
new flagship centre in Bengaluru
●
Biopeak is focused on strengthening healthspan
at a population level through clinically grounded, India-first care models
Bengaluru,
India, February 3, 2026: Biopeak, India’s
first longevity and health optimisation brand, has raised 2.7Mn in its latest
funding round led by repeat investor Nikhil Kamath. The follow-on investment
reflects continued conviction in Biopeak’s work to build structured, preventive
care systems for longevity in India.
While
India has made significant progress in acute and episodic care, organised
clinical models focused on early detection, longitudinal tracking, and
healthspan remain limited. Biopeak is addressing this gap by building
multidisciplinary specialist-led programs that combine diagnostics, proprietary
AI-driven insights, targeted clinical interventions, and sustained follow-up
over time. Its approach is designed around Indian health profiles and disease
patterns, enabling early risk identification, health optimisation, and
supported recovery and regeneration.
Over
the past year, Biopeak has continued to expand its clinical programs and deliver
measurable outcomes for clients, reflecting growing demand for structured,
specialist-led preventive and longevity care. The capital will be used to
expand Biopeak’s presence and deepen capabilities across diagnostics,
proprietary AI, research, and program development. This includes the launch of
a new flagship centre in Bengaluru, continued investment in clinical longevity
programs, and team expansion across clinical, research, product, and
operations. Building on growing consumer acceptance, Biopeak is strengthening
its network of global advisors and institutional partners to advance protocol
development and clinical governance.
Commenting
on the fundraise, Rishi Pardal, Co-founder and CEO, Biopeak, said,
“In India, we’re seeing a real shift in how people think about health, not just
when something goes wrong, but how they stay well over time. What’s been
missing is a clinical system that connects diagnostics, specialists, and
follow-up into one long-term view of health. That’s what we’re focused on building
at Biopeak. The validation of the model over the past year has given investors
the confidence to deepen their commitment, and Nikhil’s continued support
reflects a shared belief that longevity in India needs to be built
carefully,with strong clinical foundations and the right partnerships.”
Biopeak
has steadily expanded its clinical programs and patient engagement as interest
in structured preventive and longevity-focused care grows. The company’s model
centres on multidisciplinary specialist teams supported by diagnostics and
longitudinal health data, enabling more informed and consistent clinical
decision-making over time.
About
Biopeak
Founded
by Rishi Pardal and Shiva Subramanian, Biopeak is India’s first longevity and
health optimisation brand, delivering AI-driven, science-backed longevity
programs tailored for high achievers, CXOs, and women. By combining advanced
diagnostics, a multidisciplinary team of specialists, wearable data, and global health insights
adapted to Indian biology, Biopeak helps individuals optimize performance,
resilience, and well-being. For more information, visit: https://biopeak.com/
